---
title: "Breakthrough trial LT3001 shows functional improvement in patients with acute ischemic stroke, ineligible for standard therapies. Presented at conference."
description: "Results from a Phase 2 trial reveal promising findings for patients who cannot undergo standard reperfusion therapies. This data was presented at the International Stroke Conference and highlights the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275169189.md"
published_at: "2026-02-06T20:01:45.000Z"
---

# Breakthrough trial LT3001 shows functional improvement in patients with acute ischemic stroke, ineligible for standard therapies. Presented at conference.

> Results from a Phase 2 trial reveal promising findings for patients who cannot undergo standard reperfusion therapies. This data was presented at the International Stroke Conference and highlights the efficacy of LT3001 in providing significant functional improvements for patients with disabling Acute Ischemic Stroke (AIS). The trial showcased that LT3001 delivers meaningful outcomes for patients ineligible for standard treatments.

Results from a Phase 2 trial reveal promising findings for patients who cannot undergo standard reperfusion therapies. This data was presented at the International Stroke Conference and highlights the efficacy of LT3001 in providing significant functional improvements for patients with disabling Acute Ischemic Stroke (AIS). The trial showcased that LT3001 delivers meaningful outcomes for patients ineligible for standard treatments.

### Related Stocks

- [601607.CN - Shanghai Pharma](https://longbridge.com/en/quote/601607.CN.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)
- [02607.HK - SH PHARMA](https://longbridge.com/en/quote/02607.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 上海醫藥獲得新加坡市場批准用於抗凝藥物 | 上海醫藥獲得新加坡抗凝藥物的市場批准 | [Link](https://longbridge.com/en/news/276822785.md) |
| 三生製藥（TRSBF）被國元證券（香港）給予買入評級 | 國元證券（香港）分析師昨日維持對三生製藥的買入評級，並設定目標價為 32.76 港元。目前，分析師對三生製藥的共識評級為強烈買入，平均目標價為 42.69 港元 | [Link](https://longbridge.com/en/news/271463736.md) |
| 前美軍戰機教官遭逮 被控未獲授權訓練中國軍方人員 | 美國司法部逮捕前空軍飛行員布朗，因其未經授權訓練中國軍方人員。布朗在中國逗留至 2023 年 12 月，近期返回美國後被捕。他被控與外國人士共謀，為中國空軍飛行員提供戰機訓練。布朗曾在美國空軍服役 24 年，後成為國防承包商，負責訓練飛行員 | [Link](https://longbridge.com/en/news/277022708.md) |
| 上海發佈樓市「滬七條」涉放寬限購、公積金貸款及房產税政策 | 上海發布樓市「滬七條」，涉及放寬住房限購、優化住房公積金貸款及完善個人住房房產税政策。政策自 2 月 26 日起施行，旨在支持各類住房需求，促進購屋需求釋放。非滬籍居民家庭在外環外購房不限套數，外環內限購 1 套。住房公積金最高貸款額度提高 | [Link](https://longbridge.com/en/news/276845210.md) |
| 烏克蘭無人機製造商英國設廠 供應前線並深化國防合作 | 烏克蘭無人機製造商 Ukrspecsystems 在英格蘭新設工廠，投資 2 億 7100 萬美元，旨在確保烏軍關鍵裝備的穩定供應。該工廠位於麥登豪，並在埃姆塞特建設測試場。負責人表示，此舉為烏克蘭提供持續支持。英國國防部強調兩國國防產業合 | [Link](https://longbridge.com/en/news/277021522.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.